Neumora Therapeutics, INC. (NMRA) — SEC Filings

Overview

Neumora Therapeutics, INC. (NMRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Mar 30, 2026: Neumora Therapeutics, Inc. filed an S-8 form on March 30, 2026, to register securities for offering under employee benefit plans. This filing indicates the company is making shares available to its employees, likely as part of compensation or incentive programs. The filing does not involve a sale of

Sentiment Summary

Across 30 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Neumora Therapeutics, INC. is neutral.

Filing Type Overview

Neumora Therapeutics, INC. (NMRA) has filed 1 S-8, 3 10-K, 12 8-K, 6 10-Q, 2 DEF 14A, 2 8-K/A, 1 SC 13D/A, 3 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (30)

• Neumora Therapeutics Files S-8 for Employee Stock Plans — S-8 · Mar 30, 2026 Risk: low
  Neumora Therapeutics, Inc. filed an S-8 form on March 30, 2026, to register securities for offering under employee benefit plans. This filing indicates the comp
• Neumora Faces MDD Setback, Pivots on Key Neuroscience Programs — 10-K · Mar 30, 2026 Risk: high
  Neumora Therapeutics, Inc. (NMRA) is a clinical-stage biopharmaceutical company focused on neuroscience. The company is advancing several programs, including na
• Neumora Therapeutics Files 8-K on Financials — 8-K · Mar 30, 2026 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial stateme
• 8-K Filing — 8-K · Nov 21, 2025
• Neumora Narrows Losses Amid R&D Cuts, Cash Reserves Dwindle — 10-Q · Nov 6, 2025 Risk: high
  Neumora Therapeutics, Inc. (NMRA) reported a net loss of $56.755 million for the three months ended September 30, 2025, a 21.6% improvement from the $72.547 mil
• Neumora Therapeutics Files 8-K — 8-K · Oct 27, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on October 27, 2025, reporting other events and financial statements. The company, formerly known as RBNC Therapeutics,
• Neumora's Q2 Loss Widens Amid R&D Surge — 10-Q · Aug 6, 2025 Risk: high
  Neumora Therapeutics, Inc. reported a net loss of $78.5 million for the three months ended June 30, 2025, an increase from a net loss of $65.2 million for the s
• Neumora Therapeutics Files 8-K on Security Holder Vote — 8-K · May 30, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting on a matter submitted to a vote of its security holders on May 28, 2025. The company, formerl
• Neumora Therapeutics Faces Delisting Concerns — 8-K · May 16, 2025 Risk: high
  Neumora Therapeutics, Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the ef
• Neumora Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: low
  Neumora Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including marketable securities
• Neumora Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  Neumora Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for the fiscal year ending December 31, 2024. The company, formerly
• Neumora Therapeutics Files 8-K/A Amendment — 8-K/A · Apr 11, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K/A on April 11, 2025, to amend a previous filing regarding changes in its board of directors and executive compensation.
• 10-K Filing — 10-K · Mar 3, 2025
• Neumora Therapeutics Files 8-K/A Amendment — 8-K/A · Feb 21, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an amendment (8-K/A) on February 21, 2025, to its previous filing. This amendment pertains to the departure of directors or cer
• Neumora Therapeutics Files 8-K on Executive Changes — 8-K · Feb 13, 2025 Risk: low
  On February 13, 2025, Neumora Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fi
• Neumora Therapeutics Files 8-K — 8-K · Jan 13, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on financial statements and exhibits. The company, formerly known as RBNC Therapeutics, I
• Neumora Therapeutics Files 8-K — 8-K · Jan 2, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on January 2, 2025, reporting other events and financial statements. The company, formerly known as RBNC Therapeutics, I
• Arch Venture Fund XII Updates Neumora Holdings Filing — SC 13D/A · Nov 22, 2024 Risk: low
  On November 22, 2024, ARCH Venture Fund XII, L.P. and its affiliates filed an SC 13D/A amendment regarding their holdings in Neumora Therapeutics, Inc. The fili
• SC 13G Filing — SC 13G · Nov 12, 2024
• Neumora Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Neumora Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and operations, including det
• Neumora Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 6, 2024 Risk: medium
  Neumora Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business o
• Neumora Therapeutics Reports on Shareholder Vote — 8-K · Jun 14, 2024 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on June 14, 2024, reporting on a matter submitted to a vote of its security holders on June 13, 2024. The company, forme
• Neumora Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
  Neumora Therapeutics, Inc. (NMRA) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Neumora Therapeutics, Inc. filed a 10-Q report for the period end
• Neumora Therapeutics Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 25, 2024 Risk: low
  Neumora Therapeutics, Inc. (NMRA) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Annual Meeting scheduled for June 13, 2024, at 8:30 AM ET, h
• Neumora Therapeutics Closes $349.6M Public Offering — 8-K · Apr 15, 2024 Risk: medium
  On April 15, 2024, Neumora Therapeutics, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully sold 21,8
• Neumora Therapeutics Files 8-K on Financials — 8-K · Mar 7, 2024 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on March 7, 2024, reporting on its results of operations and financial condition. The filing also includes financial sta
• Neumora Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 7, 2024 Risk: medium
  Neumora Therapeutics, Inc. (NMRA) filed a Annual Report (10-K) with the SEC on March 7, 2024. Neumora Therapeutics, Inc. filed its 2023 Form 10-K on March 7, 20
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• Neumora Therapeutics Confirms Nasdaq Listing for NMRA Stock — 8-K · Jan 8, 2024
  Neumora Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose that its common stock, with a $0.0001 par value per share, is registered on Th

Risk Profile

Risk Assessment: Of NMRA's 24 recent filings, 4 were flagged as high-risk, 4 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Neumora Therapeutics, INC.'s most recent 10-K filing (Mar 30, 2026):

• Revenue: $0
• Net Income: $-230.5 million
• EPS: $-1.27
• Debt-to-Equity: 0.0
• Cash Position: $296.1 million
• Operating Margin: N/A
• Total Assets: $378.0 million
• Total Debt: $0

Industry Context

The neuroscience drug development landscape is characterized by high unmet needs and significant scientific challenges. Companies like Neumora are focused on developing novel therapies for complex neurological and psychiatric disorders, including Major Depressive Disorder and Alzheimer's disease. The industry is highly competitive, with both large pharmaceutical companies and smaller biotechs vying for breakthroughs. Regulatory hurdles and the high cost of clinical trials are significant factors influencing success.

Top Tags

corporate-governance (6) · Biotechnology (5) · 10-Q (4) · financials (4) · Clinical Trials (3) · filing (3) · amendment (3) · Neumora Therapeutics (3) · sec-filing (2) · Neuroscience (2)

Key Numbers

• Filing Date: 2026-03-30 — Date Neumora Therapeutics, Inc. submitted the S-8 form.
• Aggregate market value of common stock held by nonaffiliates: $63.3 million — as of June 30, 2025, indicating company valuation
• Shares of Common Stock outstanding: 182,040,945 — as of March 23, 2026
• Date of KOASTAL-1 results: 2025-01 — study did not demonstrate statistically significant improvement
• Expected topline data readout: Q2 2026 — for KOASTAL-2 and -3 studies for navacaprant
• Expected data readout: H2 2026 — for NMRA-511 MAD extension and NMRA-898 MAD data
• Expected initiation: Q1 2027 — of Phase 2 study for NMRA-511 in Alzheimer's disease agitation
• Half-life of NMRA-898: 80-100 hours — in humans, supporting once-daily dosing potential
• Patients enrolled: 400+ — in each of the KOASTAL-2 and -3 studies
• Adults in the United States diagnosed with MDD: 21 million — representing the potential market size for navacaprant
• MDD patients: 85% — who do not receive treatment or fail first-line therapies
• SEC Accession Number: 0001193125-26-130372 — Unique identifier for this specific filing
• Cash and cash equivalents: $129.071M — Decreased from $142.148M at Dec 31, 2024
• Short-term marketable securities: $42.454M — Decreased from $165.430M at Dec 31, 2024
• Net loss (Q3 2025): $56.755M — Improved from $72.547M in Q3 2024

Related Companies

AMGN · VYGR · SAGE · AXSM

Frequently Asked Questions